sulfasalazine has been researched along with Blood Pressure, High in 8 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 7.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 5.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| "Plasma free metanephrines or urinary fractionated metanephrines are the biochemical tests of choice for the diagnosis of pheochromocytoma as they have greater sensitivity and specificity than catecholamines for pheochromocytoma detection." | 3.96 | Case report of a phantom pheochromocytoma. ( Costelloe, SJ; Joyce, CM; Melvin, A; O'Halloran, DJ; O'Shea, PM, 2020) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "To compare the risk of incident hypertension between initiators of tumor necrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritis patients taking methotrexate monotherapy." | 3.83 | Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. ( Danaei, G; Desai, RJ; Kim, SC; Liao, KP; Schneeweiss, S; Solomon, DH, 2016) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 3.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Sulfasalazine was not able to rescue fetal growth, in male or female fetuses." | 1.91 | Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model. ( Beard, S; Binder, NK; Brownfoot, FC; de Alwis, N; Hannan, NJ; Harper, A; Kadife, E; Kaitu'u-Lino, TJ, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Binder, NK | 1 |
| de Alwis, N | 1 |
| Beard, S | 1 |
| Kadife, E | 1 |
| Harper, A | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Brownfoot, FC | 1 |
| Hannan, NJ | 1 |
| Joyce, CM | 1 |
| Melvin, A | 1 |
| O'Shea, PM | 1 |
| Costelloe, SJ | 1 |
| O'Halloran, DJ | 1 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 1 |
| George, M | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 1 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 1 |
| Uutela, T | 1 |
| Kautiainen, H | 1 |
| Järvenpää, S | 1 |
| Salomaa, S | 1 |
| Hakala, M | 1 |
| Häkkinen, A | 1 |
| Desai, RJ | 1 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Danaei, G | 1 |
| Liao, KP | 1 |
| Kim, SC | 1 |
| Wu, LC | 1 |
| Leong, PY | 1 |
| Yeo, KJ | 1 |
| Li, TY | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Handler, J | 1 |
| Jewell, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
8 other studies available for sulfasalazine and Blood Pressure, High
| Article | Year |
|---|---|
Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
Topics: Animals; Blood Pressure; Disease Models, Animal; Female; Humans; Hypertension; Male; Mice; Nitric Ox | 2023 |
Case report of a phantom pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Chromatography, Liquid; Chromogranin A; False Positive React | 2020 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine | 2016 |
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis | 2016 |
Hydralazine-induced lupus erythematosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Drug Therapy, Combination; F | 2012 |
Benign intracranial hypertension and ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Eye Manifestations; Female; Humans; Hydrocortisone; Hypertension; Intrac | 1972 |